KRESLADI
marnetegragene autotemcelgene therapylentiviral ITGB2 transfer (LAD-I)
Fanconi Anemia
Filed
1 program·1 trial·View drug →
DashboardSell23,715$15.77−$374.1KSell11,458$13.55−$155.2KSell15,131$16.90−$255.7K Infectious DiseaseCo-Investigator$732.1K6Internal MedicineResearch Grant$498.6K7Infectious DiseaseEquity / Ownership$432.4K4Infectious DiseaseCo-Investigator$359.2K5Internal MedicineCo-Investigator$309.1K2Internal MedicineEquity / Ownership$150.0K2Internal MedicineCo-Investigator$146.6K4Infectious DiseaseCo-Investigator$66.0K2
RCKTNASDAQ
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. · Cranbury, NJ · founded 2015
Rocket Pharmaceuticals is a Cranbury, New Jersey biotech developing one-time gene therapies for rare pediatric diseases. The platform uses two delivery technologies: lentiviral vectors that integrate a working copy of a missing gene into a patient's blood stem cells (used for Fanconi anemia, leukocyte adhesion deficiency, and pyruvate kinase deficiency), and AAV-based gene therapy delivered intravenously for Danon disease, a fatal cardiomyopathy in young patients.
- Lead asset
- KRESLADI · Filed · Fanconi Anemia
- gene therapy · lentiviral ITGB2 transfer (LAD-I)
- Pipeline
- 1 drug · 1 program
- 1 Rare Disease
- Modalities
- gene therapy×1
FocusGene TherapyRare Disease
$9.20-22.82%1Y
RCKT · daily close · illustrative · 0 catalysts marked
1Y high$13.671Y low$8.94range$4.73(53%)past catalysts
Peers in this space
SRPT$2.8B
Sarepta Therapeutics
Rel.
0.47
Rare Diseasegene therapy
1 programmatch: sector + modality
BMRN$11.2B
BioMarin
Rel.
0.55
Rare Diseasepeptide
1 programmatch: sector
FOLD$2.9B
Amicus Therapeutics
Rel.
0.59
Rare Diseasesmall molecule
1 programmatch: sector
NTLA$1.9B
Intellia
Rel.
0.31
Immunologygene therapy
1 programmatch: modality
VERV$540M
Verve Therapeutics
Rel.
0.28
Cardio-Renalgene therapy
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed1
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Nov 1, 2024ReadoutKRESLADI — Phase 2b Topline Met Primary EndpointNegative-40.5%-16.7%-29.9%
Sep 2, 2024ReadoutKRESLADI — Phase 3 Topline — Mixed ResultMixed-37.1%+38.4%+21.2%
Jan 6, 2024Enroll.KRESLADI — Pivotal Enrollment CompletePositive+6.6%+6.7%+2.6%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 3 transactions · 3 insiders
Net flow
−$785.0K
Buys
$0
0 txns
Sells
$785.0K
3 txns
Largest
−$374.1K
Director sell
Net flow per quarter · last 8Q
5 txns · sum −$752K
24Q325Q125Q326Q126Q2
buys · $320Ksells · $1.07M
Insider · roleActionSharesPriceValueDate
A. Iyer
Director
Apr 24, 2026
P. Voss
COO
Apr 19, 2026
A. Reyes
SVP
Apr 2, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
2 trades · 2 members
Est. net flow
−$150K
midpoint · brackets only
Buys
0
Sells
2
Party mix
1 D0 R1 I
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Sell$50K–$100K~$75KselfRep. K. Linville
House · WA
Mar 15, 2026
filed +5d
I
Sell$50K–$100K~$75KselfSen. F. Park
Senate · ME
May 2, 2025
filed +37d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
7 ETFs hold the position
Held by ETFs
$71.9M
aggregate position
Of market cap
9.98%
aggregate ETF share
Top holder
ARKG2.85%
ARK Genomic Revolution ETF
TickerETF · familyThemeNAV% of NAVPosition
ARKGGene editing$1.20B2.85%$34.2M
ARK Genomic Revolution ETF
ARK
XBIBroad biotech$7.90B0.18%$14.2M
SPDR S&P Biotech ETF
SPDR
IDNAGenomics$200.0M4.64%$9.3M
iShares Genomics Immunology Healthcare
iShares
SBIOSmall-cap biotech$110.0M6.44%$7.1M
ALPS Medical Breakthroughs ETF
First Trust
GNOMGenomics$90.0M5.32%$4.8M
Global X Genomics & Biotechnology
VanEck
BBCSmall-cap biotech$60.0M3.16%$1.9M
Virtus LifeSci Biotech Clinical Trials
WisdomTree
PBEBroad biotech$175.0M0.22%$385K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
8 physicians paid · 32 disclosed records
Total 2025+2024
$2.69M
YoY
+36%
Co-Investigator$1.47MEquity / Ownership$845.4KResearch Grant$230.8KConsulting$73.8KSpeaking$64.4KTravel & Lodging$11.2KFood & Beverage$858
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Olivia Park
Johns Hopkins
Dr. Sofia Iyer
Stanford Medicine
Dr. Anita Walsh
Duke University
Dr. Sarah Iyer
Mass General Hospital
Dr. Anita Romano
University of Michigan
Dr. Daniel Greene
Penn Medicine
Dr. Sarah Lindberg
MD Anderson
Dr. Charles Murphy
Memorial Sloan Kettering
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
No lobbying disclosures filed with the Senate LDA database in window.
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$6.6M
across all programs
Active
$0
option periods incl.
Top agency
NIH / NCI$6.6M
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NCIcompleted$6.6MOct 2023→ Apr 2025
Immuno-Oncology Combination Trial Sponsorship
Cooperative Agreement · NIH-58188195
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
2 granted · 1 pending
Total in portfolio
3
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2037
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2026/2641647 A1Process
Scalable cell-line manufacturing for KRESLADI
B. Reyes + 1 · KRESLADI
pendingfiled Apr 2026
in prosecution
12,496,209Process
Scalable cell-line manufacturing for KRESLADI
R. Reyes + 1 · KRESLADI
grantedfiled Apr 2017
exp. Apr 2037
11.0y left
10,659,234Method of Use
Combination therapy comprising KRESLADI
B. Park + 1 · KRESLADI
grantedfiled Apr 2017
exp. Apr 2037
11.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
6 items from 4 categories
corporate2regulatory2earnings1clinical1
just now
RCKT provides quarterly cash position and operating runway update
Business Wire·earnings
2d ago
RCKT adds independent director to Board
PR Newswire·corporate
5d ago
EMA validates RCKT's Marketing Authorization Application for KRESLADI
Endpoints News$·regulatory
6d ago
RCKT doses first patient in Phase 3 KRESLADI study
Endpoints News$·clinical
2mo ago
FDA grants Breakthrough Therapy Designation to RCKT's KRESLADI
Endpoints News$·regulatory
3mo ago
RCKT provides corporate update at investor conference
Business Wire·corporate
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$9.20
Open
$9.13
Day Δ
+0.07
+0.77%
Day range
$9.07 – $9.26
52W range
$8.94 – $13.67
Avg daily volume
517K
Valuation & ownership
Enterprise value
$546M
Shares out
78.26M
Float
68.09M
Insider %
1.58%
Institutional %
36.58%
Beta
1.08
vs SPY · 52w
Balance sheet & burn
Cash + invest
$357M
Total debt
$58M
Debt / equity
0.58
Cash burn / Q
$48M
R&D spend TTM
$206M
58% of cash
ATM available
$166M
dilution risk
Earnings
EPS latest
$-0.13
EPS Δ vs prior
+0.18
EPS estimate
$-0.15
next quarter
EPS prior
$-0.31
Next earnings
May 11, 2026
Rev guidance
$9M